Mobility Life: Monitoring Mobility in Daily Lives of People with Neurological Disease

项目摘要 福尔斯是受伤、住院、疗养院入院和生活质量下降的主要原因， 患有神经系统疾病的人虽然人们一致认为，行动不便是大多数福尔斯的基础， 在实验室环境之外评估这些复杂的能力是非常困难的。简短的临床检查 不能准确地反映真实的生活环境中的日常功能移动性。有福尔斯跌倒风险的患者将贝内 从一个系统，他们可以很容易地使用来衡量他们的日常流动性，评估流动性波动一整天， 评估他们跌倒的风险，并衡量旨在改善其功能活动性的干预措施的效果 减少他们的福尔斯。目前还没有商业技术来连续监测流动性的波动， 量化正常活动期间自然环境中的跌倒风险。 我们开发并验证了一个不引人注目的系统，称为移动生活，客观地描述步态， 通过可穿戴惯性传感器在自发活动期间转动。在第二阶段，我们将开发一个 用于连续监测步态的仪器化脚踝包裹，开发用户界面以支持临床研究， 制定报告，显示临床实践中跌倒风险的迹象，并彻底验证和验证我们的 技术.我们还将确定哪些指标最能指示跌倒风险，并确定规范值 对于与预期患者人群相同年龄范围的非跌倒者。我们的具体目标是： AIM岛技术开发：为Mobility Life的临床实践做好准备。 ·里程碑1：开发用于连续步态监测的仪器化弹性踝部绷带（SmartSox）。 ·里程碑2：制定有用的临床报告，以传达患者的日常活动障碍，波动， 坠落风险 ·里程碑3：完成系统验证和确认，为FDA 510（k）许可做准备， 市场 Aim II.临床研究：展示Mobility Life的临床效用，以监测 神经系统患者的功能活动性和跌倒风险。 ·里程碑4：确定哪些日常生活活动障碍最能预测PD患者的跌倒风险，或 女士 ·里程碑5：制定健康年龄匹配受试者的功能活动完整性的参考值。

Project Summary Falls are the leading cause of injuries, hospital visits, nursing home admissions, and reduced quality of life for people with neurological disorders. Although there is consensus that impaired mobility is the basis for most falls, it is very difficult to evaluate these complex abilities outside a laboratory setting. Brief clinical examinations do not accurately reflect daily, functional mobility in real life environments. Patients at risk of falls would benefit from a system they can easily use to measure their daily mobility, assess mobility fluctuations throughout the day, evaluate their risk of falling, and measure effects of interventions aimed at improving their functional mobility and reducing their falls. No commercial technology yet exists to continuously monitor fluctuations in mobility or quantify fall risk in natural environments during normal activities. We developed and validated an unobtrusive system, called Mobility Life, to objectively characterize gait and turning during spontaneous activities with wearable inertial sensors. During this Phase II, we will develop an instrumented ankle wrap for continuous monitoring of gait, develop a user interface to support clinical research, develop reports that show indications of fall risk for clinical practice, and thoroughly verify and validate our technology. We will also determine which metrics are most indicative of fall risk and determine normative values for non-fallers in the same age range as the expected patient populations. Our specific aims are: AIM I. Technology Development: Prepare Mobility Life for clinical practice. · Milestone 1: Develop an instrumented elastic ankle bandage (SmartSox) for continuous gait monitoring. · Milestone 2: Develop useful clinical reports to convey patients' daily mobility impairments, fluctuations, and fall risk. · Milestone 3: Complete the system verification and validation in preparation for FDA 510(k) clearance to market. Aim II. Clinical Research: Demonstrate the clinical utility of Mobility Life to monitor quality of functional mobility and fall risk in neurological patients. · Milestone 4: Determine which daily life mobility impairments best predict fall risk in patients with PD or MS. · Milestone 5: Develop reference values for integrity of functional mobility in healthy age-matched subjects.